151 related articles for article (PubMed ID: 21123151)
41. Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study.
Kakolyris S; Ziras N; Vamvakas L; Varthalitis J; Papakotoulas P; Syrigos K; Vardakis N; Kalykaki A; Amarantidis K; Georgoulias V
Lung Cancer; 2006 Dec; 54(3):347-52. PubMed ID: 17030075
[TBL] [Abstract][Full Text] [Related]
42. Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.
Dussol AS; Joly MO; Vercherat C; Forestier J; Hervieu V; Scoazec JY; Lombard-Bohas C; Walter T
Cancer; 2015 Oct; 121(19):3428-34. PubMed ID: 26058464
[TBL] [Abstract][Full Text] [Related]
43. GEMOX: An Active Regimen for the Treatment of Luminal and Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Rizzi A; Aroldi F; Bertocchi P; Prochilo T; Mutti S; Savelli G; Fraccon AP; Zaniboni A
Chemotherapy; 2017; 62(1):30-33. PubMed ID: 27287263
[TBL] [Abstract][Full Text] [Related]
44. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.
Patrikidou A; Sinapi I; Regnault H; Fayard F; Bouattour M; Fartoux L; Faivre S; Malka D; Ducreux M; Boige V
Invest New Drugs; 2014 Oct; 32(5):1028-35. PubMed ID: 24748335
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.
Harnett P; Buck M; Beale P; Goldrick A; Allan S; Fitzharris B; De Souza P; Links M; Kalimi G; Davies T; Stuart-Harris R
Int J Gynecol Cancer; 2007; 17(2):359-66. PubMed ID: 17362313
[TBL] [Abstract][Full Text] [Related]
46. Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study.
Kakolyris S; Kalbakis K; Potamianou A; Malamos N; Vamvakas L; Christophillakis C; Tselepatiotis E; Giassas S; Mavroudis D; Amarantidis K; Georgoulias V
Oncology; 2006; 70(4):273-9. PubMed ID: 17047398
[TBL] [Abstract][Full Text] [Related]
47. [Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
Jiang Y; Zhong H; He P; Zheng L; Yang K
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):472-5. PubMed ID: 26463154
[TBL] [Abstract][Full Text] [Related]
48. Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients.
Caruba T; Cottu PH; Madelaine-Chambrin I; Espié M; Misset JL; Gross-Goupil M
Breast J; 2007; 13(2):165-71. PubMed ID: 17319858
[TBL] [Abstract][Full Text] [Related]
49. Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases.
Ikeda Y; Takano M; Oda K; Kouta H; Goto T; Kudoh K; Sasaki N; Kita T; Kikuchi Y
Int J Gynecol Cancer; 2013 Feb; 23(2):355-60. PubMed ID: 23358182
[TBL] [Abstract][Full Text] [Related]
50. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report.
Mavroudis D; Kourousis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Samonis G; Georgoulias V
Semin Oncol; 2000 Feb; 27(1 Suppl 2):25-30. PubMed ID: 10697033
[TBL] [Abstract][Full Text] [Related]
51. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Safran H; Miner T; Resnick M; Dipetrillo T; McNulty B; Evans D; Joseph P; Plette A; Millis R; Sears D; Gutman N; Kennedy T
Am J Clin Oncol; 2008 Apr; 31(2):140-4. PubMed ID: 18391597
[TBL] [Abstract][Full Text] [Related]
52. Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual.
Lopes G; Quesada J; Ahn E; Flores A; Ribeiro A; Rocha-Lima CM
Clin Colorectal Cancer; 2007 Sep; 6(9):641-5. PubMed ID: 17945036
[TBL] [Abstract][Full Text] [Related]
53. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.
Rodríguez J; Gutierrez A; Palacios A; Navarrete M; Blancas I; Alarcón J; Caballero MD; De Mattos SF; Gines J; Martínez J; Lopez A
Leuk Lymphoma; 2007 Nov; 48(11):2172-8. PubMed ID: 17990179
[TBL] [Abstract][Full Text] [Related]
54. Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
Elshebeiny M; Almorsy W
J Egypt Natl Canc Inst; 2016 Sep; 28(3):183-9. PubMed ID: 27237370
[TBL] [Abstract][Full Text] [Related]
55. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.
Carrato A; Vieitez JM; Benavides M; Rodriguez-Garrote M; Castillo A; Ogalla GD; Bermejo LG; Ruiz de Mena I; Guillén-Ponce C; Aranda E;
Eur J Cancer; 2020 Nov; 139():51-58. PubMed ID: 32977220
[TBL] [Abstract][Full Text] [Related]
56. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
57. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
Jang JS; Lim HY; Hwang IG; Song HS; Yoo N; Yoon S; Kim YH; Park E; Byun JH; Lee MA; Oh SJ; Lee KH; Kim BS; Oh SC; Kim SY; Lee SJ
Cancer Chemother Pharmacol; 2010 Mar; 65(4):641-7. PubMed ID: 19652971
[TBL] [Abstract][Full Text] [Related]
58. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Oh SY; Kim HJ; Kim TH; Lee GW; Kim HG; Jeong CY; Kwon HC; Kang JH
Invest New Drugs; 2010 Jun; 28(3):343-9. PubMed ID: 19444385
[TBL] [Abstract][Full Text] [Related]
59. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.
Gruenberger B; Schueller J; Heubrandtner U; Wrba F; Tamandl D; Kaczirek K; Roka R; Freimann-Pircher S; Gruenberger T
Lancet Oncol; 2010 Dec; 11(12):1142-8. PubMed ID: 21071270
[TBL] [Abstract][Full Text] [Related]
60. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
Park I; Kim BS; Lim HY; Kim HJ; Lee HJ; Choi YJ; Park KH; Lee KH; Yoon S; Hong B; Hong JH; Ahn H; Lee JL
Eur J Cancer; 2020 Mar; 127():183-190. PubMed ID: 31668839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
